228579-13-3

Upstream product

• 150-76-5 4-methoxy-phenol 
• 592508-73-1 C₁₆H₁₆O₃ 
• 459-57-4 4-fluorobenzaldehyde 
• 78725-47-0 4-(4-methoxyphenoxy)benzaldehyde 
• 10181-93-8 4-(4-methoxyphenoxy)phenol 

Downstream Products

• 228579-10-0 4-(3-bromopropoxy)-3-propylphenyl phenyl ether 
• 656235-29-9 2-imino-5-(4-{3-[4-(4-methoxy-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-thiazolidin-4-one 
• 606966-70-5 hydroxy-(3-{3-[4-(4-methoxy-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-acetic acid methyl ester 
• 592508-57-1 hydroxy-(4-{3-[4-(4-methoxy-phenoxy)-2-propyl-phenoxy]-propoxy}-phenyl)-acetic acid methyl ester 

Relevant academic research and scientific papers

ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES

Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones of formula (I) are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.

5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents

A novel series of 5-aryl thiazolidine-2,4-diones based dual PPARα/γ agonists was identified. A number of highly potent and orally bioavailable analogues were synthesized. Efficacy study results of some of these analogues in the db/db mice model of type 2 diabetes showed them superior to rosiglitazone in correcting hyperglycemia and hypertriglyceridemia.